StevenLawrenceMcAfeeMD

Instructor in Medicine, Massachusetts General Hospital

Dr. McAfee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
100 Blossom Street
Cox 640 Hematology Oncology Associates
Boston, MA 02114
Phone+1 617-724-1124

Fax+1 617-724-1126

MedStar Health Georgetown UniversityFellowship, Hematology and Medical Oncology, 1992 - 1993
MedStart Georgetown University HospitalFellowship, Medical Oncology, 1990 - 1992
Presbyterian Medical Center of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1987 - 1990
Tufts University School of MedicineClass of 1987

PubMed

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.
Zachariah DeFilipp, Haesook T Kim, Laura W Knight, Suzanne M O'Connor, Shilton E Dhaver
Blood. 2025-03-19
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.
Philip C Amrein, Frederic I Preffer, Geoffrey Fell, Eyal C Attar, Rupa Narayan
Leukemia & Lymphoma. 2025-03-12
1 citations
Outcomes of a Formal Hematopoietic Cell Transplantation Survivorship Program on Screening for Late Effects.
Richard A Newcomb, Lucy Gao, Julie Vanderklish, Alexandra Tse, Meredith Saylor
Transplantation and Cellular Therapy. 2024-07-01

Abstracts/Posters

Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases
Steven L McAfee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
Steven McAfee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018